 |
|
Statins may treat blood vessel disorder that can lead to fatal strokes
January 27, 2009Cholesterol drugs may offer first inexpensive, easy therapy for CCM
SALT LAKE CITY - In a finding that could save thousands of lives a year, University of Utah School of Medicine researchers have shown that a blood vessel disorder leading to unpredictable, sometimes fatal, hemorrhagic strokes, seizures, paralysis or other problems is treatable with the same statin drugs that millions of people take to control high cholesterol.
If the results of a study in mice are confirmed in a pilot trial with people, statins could provide a safe, inexpensive treatment for cerebral cavernous malformation (CCM), a disorder with no known drug therapy, according to U of U cardiologist Dean Y. Li, M.D., Ph.D., director of the Molecular Medicine Program and corresponding author of a study published Jan. 18 in Nature Medicine online.
"Brain surgery or radiation treatment has been the only option for CCM patients. But because of the risks in those operations, neurosurgeons are reluctant to perform them unless the patient is in immediate danger," Li said. "Our study proposes a potential strategy for a simple drug therapy that could cost only a few dollars a month at a pharmacy. However, our animal studies must first be evaluated in a pilot clinical trial being initiated."
Kevin J. Whitehead, M.D., also a cardiologist, assistant professor of internal medicine, and first author of the study, now is recruiting 50 to 100 people diagnosed with CCM to join a pilot trial of statins.
CCM is a disorder in which blood vessels in the brain become dilated and weakened, and leak blood, causing strokes, headaches, seizures or other problems. Diagnosing CCM can be problematic. Some people are diagnosed after experiencing symptoms and undergoing an MRI; others find out they have CCM during an MRI for an unrelated problem. An estimated 25 percent of people with CCM experience no symptoms and never know they have it. In worst-case scenarios, "people don't know they have CCMs until they suffer from an acute brain attack," Li said.
According to Connie Lee of the Angioma Alliance, "Cavernous angioma or cerebral cavernous malformation is a common but little known illness that can strike with devastating consequences for individuals in any stage of life. The disease has affected the strongest among us, including prominent athletes such as the Olympic superstar, Florence Griffith Joyner, and the Tour De France champion, Alberto Contador. In its hereditary form, it is especially prevalent in members of the original Hispanic families that settled the American Southwest."
Although the precise number of people with CCM is not known, it's estimated up to 0.5 percent of the U.S. population or about 1.5 million people may have some form of CCM, according to Whitehead. "Statin therapy, particularly, could benefit people who are genetically predisposed to CCM," he said. "Of vital importance is the impact this research might have on the large number of our Hispanic population in the Southwest and Rocky Mountain West who carry a gene mutation, passed from common ancestors, that predisposes them to CCM."
Whitehead and Li suspect statins, such as Zocor, Lipitor, and similar drugs, treat CCM by stabilizing blood vessels so they don't leak.
CCM can be inherited genetically or occur sporadically. Three known genes have been associated with genetic-related CCM, but the role of those genes, Ccm1, Ccm2, and Ccm3, has been unclear. Whitehead and Li demonstrated that without Ccm2, the endothelium, a thin, inner lining of cells that forms a blood vessel's tubular passage for blood flow, does not form properly. When that happens, blood vessels can become weak and dilated, allowing them to leak.
In mice with two distinct mutations of Ccm2, meaning the gene's function was knocked out, the researchers observed increased activity in Rho, an enzyme that regulates endothelium formation. Li and Whitehead theorized that increased Rho activity in endothelial cells might lead to the blood vessel defects seen in CCM patients. They tested their hypothesis by administering simvastatin, which is known to inhibit Rho activity, to mouse models with the Ccm2 mutations and saw that the drugs strengthened the damaged blood vessels in the mice."
Eugene Golanov, M.D., Ph.D., a program director at the National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health, said Li's and Whitehead's study is an important work. "By attacking this disease from many angles - including genetic, biochemical and pharmacological approaches - Dr. Li's team has shed new light on the mechanism of the disease and a potential drug therapy, " Golanov said. "Their success illustrates the importance of encouraging teams of scientists and physicians across institutions and disciplines to target familial stroke diseases such as cerebral cavernous malformations."
University of Utah Health Sciences
"Brain surgery or radiation treatment has been the only option for CCM patients. But because of the risks in those operations, neurosurgeons are reluctant to perform them unless the patient is in immediate danger," Li said. "Our study proposes a potential strategy for a simple drug therapy that could cost only a few dollars a month at a pharmacy. However, our animal studies must first be evaluated in a pilot clinical trial being initiated."
Kevin J. Whitehead, M.D., also a cardiologist, assistant professor of internal medicine, and first author of the study, now is recruiting 50 to 100 people diagnosed with CCM to join a pilot trial of statins.
CCM is a disorder in which blood vessels in the brain become dilated and weakened, and leak blood, causing strokes, headaches, seizures or other problems. Diagnosing CCM can be problematic. Some people are diagnosed after experiencing symptoms and undergoing an MRI; others find out they have CCM during an MRI for an unrelated problem. An estimated 25 percent of people with CCM experience no symptoms and never know they have it. In worst-case scenarios, "people don't know they have CCMs until they suffer from an acute brain attack," Li said.
According to Connie Lee of the Angioma Alliance, "Cavernous angioma or cerebral cavernous malformation is a common but little known illness that can strike with devastating consequences for individuals in any stage of life. The disease has affected the strongest among us, including prominent athletes such as the Olympic superstar, Florence Griffith Joyner, and the Tour De France champion, Alberto Contador. In its hereditary form, it is especially prevalent in members of the original Hispanic families that settled the American Southwest."
Although the precise number of people with CCM is not known, it's estimated up to 0.5 percent of the U.S. population or about 1.5 million people may have some form of CCM, according to Whitehead. "Statin therapy, particularly, could benefit people who are genetically predisposed to CCM," he said. "Of vital importance is the impact this research might have on the large number of our Hispanic population in the Southwest and Rocky Mountain West who carry a gene mutation, passed from common ancestors, that predisposes them to CCM."
Whitehead and Li suspect statins, such as Zocor, Lipitor, and similar drugs, treat CCM by stabilizing blood vessels so they don't leak.
CCM can be inherited genetically or occur sporadically. Three known genes have been associated with genetic-related CCM, but the role of those genes, Ccm1, Ccm2, and Ccm3, has been unclear. Whitehead and Li demonstrated that without Ccm2, the endothelium, a thin, inner lining of cells that forms a blood vessel's tubular passage for blood flow, does not form properly. When that happens, blood vessels can become weak and dilated, allowing them to leak.
In mice with two distinct mutations of Ccm2, meaning the gene's function was knocked out, the researchers observed increased activity in Rho, an enzyme that regulates endothelium formation. Li and Whitehead theorized that increased Rho activity in endothelial cells might lead to the blood vessel defects seen in CCM patients. They tested their hypothesis by administering simvastatin, which is known to inhibit Rho activity, to mouse models with the Ccm2 mutations and saw that the drugs strengthened the damaged blood vessels in the mice."
Eugene Golanov, M.D., Ph.D., a program director at the National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health, said Li's and Whitehead's study is an important work. "By attacking this disease from many angles - including genetic, biochemical and pharmacological approaches - Dr. Li's team has shed new light on the mechanism of the disease and a potential drug therapy, " Golanov said. "Their success illustrates the importance of encouraging teams of scientists and physicians across institutions and disciplines to target familial stroke diseases such as cerebral cavernous malformations."
University of Utah Health Sciences
Statins Current Events and Statins News RSSWidely used cholesterol-lowering drug may prevent progression
Simvastatin, a commonly used, cholesterol-lowering drug, may prevent Parkinson's disease from progressing further. Neurological researchers at Rush University Medical Center conducted a study examining the use of the FDA-approved medication in mice with Parkinson's disease and found that the drug successfully reverses the biochemical, cellular and anatomical changes caused by the disease.
Statins show dramatic drug and cell dependent effects in the brain
Besides their tremendous value in treating high cholesterol and lowering the risk of heart disease, statins have also been reported to potentially lower the risks of other diseases, such as dementia.
Cholesterol-lowering medicines may be effective against cancer
Statins lower cholesterol by blocking certain enzymes involved in our metabolism.
Adding ezetimibe to atorvastatin improves lipid control
Adding ezetimibe to atorvastatin significantly boosted the attainment of lipid targets as specified by both Canadian and European guidelines in elderly patients aged 65 and older and the combination produced superior results than simply increasing the dose of atorvastatin alone.
Use of statins favors the wealthy, creating new social disparities in cholesterol
Since the introduction of statins to treat high cholesterol, the decline in lipid levels experienced by the wealthy has been double that experienced by the poor.
Women with Atrial Fibrillation Are at Significantly Higher Risk of Stroke and Death Compared to Men and Receive Less Attention
Even though the incidence of atrial fibrillation is higher in men than women, a review of past studies and medical literature completed by cardiac experts at Rush University Medical Center shows that women are more likely than men to experience symptomatic attacks, a higher frequency of recurrences, and significantly higher heart rates during atrial fibrillation, which increases the risk of stroke.
Pre-hospital organization: The first links in the chain of survival for heart attack patients
Mortality rate following a heart attack has fallen by more than 50% in Europe over the past 25 years. However, because only minor advances in the medical treatment of AMI are expected over the next decade, it is through organisational changes in the pre-hospital phase that mortality rate will continue this decline to below 5%.
Fatostatin' is a turnoff for fat genes
A small molecule earlier found to have both anti-fat and anti-cancer abilities works as a literal turnoff for fat-making genes, according to a new report in the August 28th issue of the journal Chemistry and Biology, a Cell Press journal.
Study reveals mounting evidence of fish oil's heart health benefits
There is mounting evidence that omega-3 fatty acids from fish or fish oil supplements not only help prevent cardiovascular diseases in healthy individuals, but also reduce the incidence of cardiac events and mortality in patients with existing heart disease.
New tool finds best heart disease and stroke treatments for patients with diabetes
Researchers from North Carolina State University and Mayo Clinic have developed a computer model that medical doctors can use to determine the best time to begin using statin therapy in diabetes patients to help prevent heart disease and stroke.
More Statins Current Events and Statins News Articles
 |
Statin Drugs Side Effects and the Misguided War on Cholesterol by Duane Graveline (Author) If you are on a statin drug or are thinking of going on a statin, this fully referenced book, Statin Drug Side Effects, is a "must read" for you. The unacceptable legacy of statin drug use at today's high doses is a trail of chronic aches and pains, numbness, weakness, confusion, fatigue, shortness of breath and even heart failure in hordes of unsuspecting victims. Only by knowing this information, and in consultation with your healthcare professional, can you make an informed decision about your health care. If you are a user of Vytorin, Lipitor, Zocor, Crestor, Mevacor, Pravachol or Lescol you must read this book. Most of the statin side effects I discuss are unknown to your busy doctor. Although knowledgeable about muscle and liver problems, few have heard of statin amnesia and... |
 |
The Statin Damage Crisis by Duane Graveline (Author), Malcolm Kendrick (Introduction) The purpose in the choice of the title The Statin Damage Crisis is to draw attention to the thousands of statin damaged people who have written to Dr Graveline about their disabling neuropathies, myopathies and a variety of neurodegenerative conditions such as ALS and Parkinsonism associated with statin use. Although much of the book's content will be familiar to readers of Statin Drugs Side Effects, ( this was originally planned as a new edition ) the Statin Damage Crisis adds much new material that Dr Graveline has learned of in the past two years. Dr Graveline states: "Early on my NASA doctors told me my amnesia response to statins was nothing but a coincidence but I persevered to write my first book, Lipitor, Thief of Memory." "Then I learned of statin damage to nerves and... |
 |
What You Must Know About Statin Drugs & Their Natural Alternatives by Jay S. Cohen (Author) |
 |
Triumph of the Heart: The Story of Statins by Jie Jack Li (Author) Over 25 million people in the U.S. alone have benefited from statins--such drugs as Lipitor, Zocor, Crestor, Pravachol, and other cholesterol-lowering medicines--in preventing stroke, heart attack, and other forms of coronary heart disease. But how did these remarkable, life-saving drugs come into being? In Triumph of the Heart, Dr. Jie Jack Li, a medicinal chemist and expert on drug discovery, tells for the first time the fascinating story of statins. Drawn from discussions with many scientists involved in the discovery and development of these drugs, the book illuminates the human side of science by revealing the role played by persistence, luck, and sudden insight that characterize major discoveries. For scientists in the drug industry, health care professionals, students of medicine,... |
 |
Natural Alternatives to Lipitor, Zocor & Other Statin Drugs: What to Use And Do to Help Lower Your Bad Cholesterol (Square One Health Guides) by Jay S. Cohen (Author) |
 |
Hidden Truth about Cholesterol-Lowering Drugs by Shane Ellison (Author) As a drug chemist for a leading pharmaceutical company I made a startling discovery: you do not have to be dependent on FDA approved drugs to avoid heart disease. In fact, research clearly shows the opposite. You don't need a single prescription drug to avoid this killer. Consider this: FDA approved drugs, used as prescribed, are killing over 125,000 people every year. Nationally, this makes prescription drugs the fourth leading cause of death after cancer, heart disease and stroke. That does not count death by medical error, which adds 98,000 deaths to this atrocity. Hypnotized by drug ads, the general public is oblivious to the deaths caused by prescription drug use. This is evidenced by their willingness to swallow whatever "the doctor ordered". This is especially true... |
 |
Cholesterol Down: Ten Simple Steps to Lower Your Cholesterol in Four Weeks--Without Prescription Drugs by Janet Brill (Author) Take Control of Your Cholesterol— Without Drugs If you are one of the nearly 100 million Americans struggling with high cholesterol, then Dr. Janet Brill offers you a revolutionary new plan for taking control of your health—without the risks of statin drugs. With Dr. Brill’s breakthrough Cholesterol Down Plan, you simply add nine “miracle foods” to your regular diet and thirty minutes of walking to your daily routine. That’s all. This straightforward and easy-to-follow program can lower your LDL (“bad”) cholesterol by as much as 47 percent in just four weeks. Cholesterol Down explains Dr. Brill’s ten-point plan as well as the science behind it. You’ll learn how each miracle food affects LDL cholesterol and how the foods work together for maximum effect,... |
 |
NOW ORGANIC RED YEAST RICE EXTRACT 600 MG - 120 Vegicaps by NOW Foods Red Yeast Rice is a unique natural product native to China thats been used in Asian traditional medical systems since approximately 800 A.D. Produced by fermenting red yeast (Monascus purpureus) with white rice, Red Yeast Rice is commonly used in cooking applications to enhance the color and flavor of foods. Peking Duck is an example of the coloration and flavor imparted by Red Yeast Rice. |
 |
Statin Boy & Cholesterol Kid by Today's Icons Wall sculpture depicting modern day icons, cholsterol and its antidote Statin pill, ready for hanging! |
 |
Radio Liberty: Statin Drugs (4 Disc Set) by Dr. Stanley "Stan" Monteith (Author), Dr. Russell Blaylock (Author), Bill Sardi (Author), Dr. Ray Strand (Author), Shane Ellison (Author), Dr. Stanley "Stan" Monteith (Narrator) There is much that is still not understood about statins, and it is increasingly apparent that they have a dark side. The major adverse effect of statins is muscle weakness and degradation, called myopathy or rhabdomyolysis, which can range from mild to severe. Understand that among low risk patients, the benefit-to-risk ratio associated with statin use is also lower. Indeed, in low-risk people, it is possible that statin-induced adverse effects may exceed the potential benefits. This is especially pertinent when we consider that, once an individual has begun to use them, statins are likely to be used for many years, Statins may have other adverse effects that are less common than myopathy, ranging from macular degeneration (central vision loss), to acute pancreatitis, worsening of... |
| © 2009 BrightSurf.com |